安圖生物(603658.SH):擬使用合計不超22.5億元閒置募集資金進行現金管理
格隆匯1月11日丨安圖生物(603658.SH)公佈,公司於2023年1月11日召開第四屆董事會第八次會議及第四屆監事會第七次會議,審議通過了《關於使用閒置募集資金進行現金管理的議案》。
本着股東利益最大化原則,為提高閒置募集資金使用效率,合理利用閒置募集資金,在確保不影響募集資金項目建設和募集資金使用的情況下,公司分別使用不超過2.8億元公開發行可轉換公司債券閒置募集資金和不超過19.7億元非公開發行股票閒置募集資金進行現金管理,選擇適當的時機,階段性購買結構性存款、大額存單等安全性高的保本型產品。以上資金額度在決議有效期內可以滾動使用,並授權董事長在額度範圍內行使該項投資決策權並簽署相關合同文件,決議有效期自董事會審議通過之日起一年有效。本事項尚在公司董事會決策權限範圍內,無需提交公司股東大會審議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.